AE adds new trials to its Clinical Trials Watch

18/01/2022

Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD).

In January 2022, five new Phase III trials have been added to the service:

• EVOKE (Novo Nordisk A/S) • EVOKE Plus (Novo Nordisk A/S)

• APOLLOE4 (Alzheon Inc.) • GREEN MEMORY (Green Valley (Shanghai) Pharmaceuticals Co)

• AHEAD 3-45 (Eisai).

Further information about the CTW is available on: https://www.alzheimer-europe.org/research/clinical-trials